GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1

被引：75

作者：

Kumar, Krishan ^{[1
,3
]}

Raza, Sania S. ^{[1
]}

Knab, Lawrence M. ^{[2
]}

Chow, Christina R. ^{[1
,4
]}

Kwok, Benjamin ^{[1
]}

Bentrem, David J. ^{[2
,3
,4
]}

Popovic, Relja ^{[1
]}

Ebine, Kazumi ^{[1
,3
]}

Licht, Jonathan D. ^{[1
,4
]}

Munshi, Hidayatullah G. ^{[1
,3
,4
]}

机构：

[1] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA

[2] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA

[3] Jesse Brown VA Med Ctr, Chicago, IL 60612 USA

[4] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

来源：

SCIENTIFIC REPORTS | 2015年 / 5卷

关键词：

EPITHELIAL-MESENCHYMAL TRANSITION; DRUG-RESISTANCE; THERAPEUTIC TARGET; PROTEIN; GROWTH; SENSITIVITY; ACTIVATION; APOPTOSIS; HEDGEHOG; PROLIFERATION;

D O I：

10.1038/srep09489

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

JQ1 and I-BET151 are selective inhibitors of BET bromodomain proteins that have efficacy against a number of different cancers. Since the effectiveness of targeted therapies is often limited by development of resistance, we examined whether it was possible for cancer cells to develop resistance to the BET inhibitor JQ1. Here we show that pancreatic cancer cells developing resistance to JQ1 demonstrate cross-resistance to I-BET151 and insensitivity to BRD4 downregulation. The resistant cells maintain expression of c-MYC, increase expression of JQ1-target genes FOSL1 and HMGA2, and demonstrate evidence of epithelial-mesenchymal transition (EMT). However, reverting EMT fails to sensitize the resistant cells to JQ1 treatment. Importantly, the JQ1-resistant cells remain dependent on c-MYC that now becomes co-regulated by high levels of GLI2. Furthermore, downregulating GLI2 re-sensitizes the resistant cells to JQ1. Overall, these results identify a mechanism by which cancer cells develop resistance to BET inhibitors.

引用

页数：9

共 56 条

[11] Three-Dimensional Collagen I Promotes Gemcitabine Resistance in Pancreatic Cancer through MT1-MMP-Mediated Expression of HMGA2
Dangi-Garimella, Surabhi
Krantz, Seth B.
Barron, Morgan R.
Shields, Mario A.
Heiferman, Michael J.
Grippo, Paul J.
Bentrem, David J.
Munshi, Hidayatullah G.
[J]. CANCER RESEARCH, 2011, 71 (03) : 1019 - 1028
[12] Rho-ROCK-Myosin Signaling Meditates Membrane Type 1 Matrix Metalloproteinase-induced Cellular Aggregation of Keratinocytes
Dangi-Garimella, Surabhi
Redig, Amanda J.
Shields, Mario A.
Siddiqui, Mohammed A.
Munshi, Hidayatullah G.
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (36) : 28363 - 28372
[13] Cancer Epigenetics: From Mechanism to Therapy
Dawson, Mark A.
Kouzarides, Tony
[J]. CELL, 2012, 150 (01) : 12 - 27
[14] Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Dawson, Mark A.
Prinjha, Rab K.
Dittmann, Antje
Giotopoulos, George
Bantscheff, Marcus
Chan, Wai-In
Robson, Samuel C.
Chung, Chun-wa
Hopf, Carsten
Savitski, Mikhail M.
Huthmacher, Carola
Gudgin, Emma
Lugo, Dave
Beinke, Soren
Chapman, Trevor D.
Roberts, Emma J.
Soden, Peter E.
Auger, Kurt R.
Mirguet, Olivier
Doehner, Konstanze
Delwel, Ruud
Burnett, Alan K.
Jeffrey, Phillip
Drewes, Gerard
Lee, Kevin
Huntly, Brian J. P.
Kouzarides, Tony
[J]. NATURE, 2011, 478 (7370) : 529 - 533
[15] PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies
De Raedt, Thomas
Beert, Eline
Pasmant, Eric
Luscan, Armelle
Brems, Hilde
Ortonne, Nicolas
Helin, Kristian
Hornick, Jason L.
Mautner, Victor
Kehrer-Sawatzki, Hildegard
Clapp, Wade
Bradner, James
Vidaud, Michel
Upadhyaya, Meena
Legius, Eric
Cichowski, Karen
[J]. NATURE, 2014, 514 (7521) : 247 - +
[16] BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, Jake E.
Issa, Ghayas C.
Lemieux, Madeleine E.
Rahl, Peter B.
Shi, Junwei
Jacobs, Hannah M.
Kastritis, Efstathios
Gilpatrick, Timothy
Paranal, Ronald M.
Qi, Jun
Chesi, Marta
Schinzel, Anna C.
McKeown, Michael R.
Heffernan, Timothy P.
Vakoc, Christopher R.
Bergsagel, P. Leif
Ghobrial, Irene M.
Richardson, Paul G.
Young, Richard A.
Hahn, William C.
Anderson, Kenneth C.
Kung, Andrew L.
Bradner, James E.
Mitsiades, Constantine S.
[J]. CELL, 2011, 146 (06) : 903 - 916
[17] Cloning of the Human GLI2 Promoter TRANSCRIPTIONAL ACTIVATION BY TRANSFORMING GROWTH FACTOR-β VIA SMAD3/β-CATENIN COOPERATION
Dennler, Sylviane
Andre, Jocelyne
Verrecchia, Franck
Mauviel, Alain
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (46) : 31523 - 31531
[18] An epigenomic approach to therapy for tamoxifen-resistant breast cancer
Feng, Qin
Zhang, Zheng
Shea, Martin J.
Creighton, Chad J.
Coarfa, Cristian
Hilsenbeck, Susan G.
Lanz, Rainer
He, Bin
Wang, Lei
Fu, Xiaoyong
Nardone, Agostina
Song, Yongcheng
Bradner, James
Mitsiades, Nicholas
Mitsiades, Constantine S.
Osborne, C. Kent
Schiff, Rachel
O'Malley, Bert W.
[J]. CELL RESEARCH, 2014, 24 (07) : 809 - 819
[19] Selective inhibition of BET bromodomains
Filippakopoulos, Panagis
Qi, Jun
Picaud, Sarah
Shen, Yao
Smith, William B.
Fedorov, Oleg
Morse, Elizabeth M.
Keates, Tracey
Hickman, Tyler T.
Felletar, Ildiko
Philpott, Martin
Munro, Shonagh
McKeown, Michael R.
Wang, Yuchuan
Christie, Amanda L.
West, Nathan
Cameron, Michael J.
Schwartz, Brian
Heightman, Tom D.
La Thangue, Nicholas
French, Christopher A.
Wiest, Olaf
Kung, Andrew L.
Knapp, Stefan
Bradner, James E.
[J]. NATURE, 2010, 468 (7327) : 1067 - 1073
[20] BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD
Fiskus, Warren
Sharma, Sunil
Qi, Jun
Shah, Bhavin
Devaraj, Santhana G. T.
Leveque, Christopher
Portier, Bryce P.
Iyer, Swaminathan
Bradner, James E.
Bhalla, Kapil N.
[J]. MOLECULAR CANCER THERAPEUTICS, 2014, 13 (10) : 2315 - 2327

← 1 2 3 4 5 6 →